nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABCB11—Dexamethasone—ankylosing spondylitis	0.104	0.149	CbGbCtD
Ponatinib—ABCG2—Sulfasalazine—ankylosing spondylitis	0.0987	0.141	CbGbCtD
Ponatinib—CYP3A5—Sulfasalazine—ankylosing spondylitis	0.0547	0.0784	CbGbCtD
Ponatinib—ABCG2—Dexamethasone—ankylosing spondylitis	0.0493	0.0706	CbGbCtD
Ponatinib—ABCB1—Methylprednisolone—ankylosing spondylitis	0.047	0.0673	CbGbCtD
Ponatinib—ABCG2—Methotrexate—ankylosing spondylitis	0.0396	0.0567	CbGbCtD
Ponatinib—ABCB1—Betamethasone—ankylosing spondylitis	0.0305	0.0438	CbGbCtD
Ponatinib—ABCB1—Prednisolone—ankylosing spondylitis	0.0301	0.0432	CbGbCtD
Ponatinib—ABCB1—Prednisone—ankylosing spondylitis	0.0285	0.0408	CbGbCtD
Ponatinib—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0281	0.0403	CbGbCtD
Ponatinib—CYP3A5—Dexamethasone—ankylosing spondylitis	0.0273	0.0391	CbGbCtD
Ponatinib—CYP2C8—Dexamethasone—ankylosing spondylitis	0.0263	0.0376	CbGbCtD
Ponatinib—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0213	0.0306	CbGbCtD
Ponatinib—CYP3A4—Betamethasone—ankylosing spondylitis	0.0183	0.0262	CbGbCtD
Ponatinib—CYP3A4—Prednisolone—ankylosing spondylitis	0.0181	0.0259	CbGbCtD
Ponatinib—ABCB1—Dexamethasone—ankylosing spondylitis	0.0178	0.0255	CbGbCtD
Ponatinib—CYP3A4—Prednisone—ankylosing spondylitis	0.0171	0.0244	CbGbCtD
Ponatinib—CYP2D6—Dexamethasone—ankylosing spondylitis	0.0167	0.024	CbGbCtD
Ponatinib—ABCB1—Methotrexate—ankylosing spondylitis	0.0143	0.0205	CbGbCtD
Ponatinib—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0106	0.0153	CbGbCtD
Ponatinib—Pancreatitis—Prednisone—ankylosing spondylitis	0.000416	0.00217	CcSEcCtD
Ponatinib—Visual impairment—Methylprednisolone—ankylosing spondylitis	0.000413	0.00216	CcSEcCtD
Ponatinib—Erythema—Prednisolone—ankylosing spondylitis	0.000406	0.00212	CcSEcCtD
Ponatinib—Eye disorder—Methylprednisolone—ankylosing spondylitis	0.0004	0.00209	CcSEcCtD
Ponatinib—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.000398	0.00208	CcSEcCtD
Ponatinib—Neutropenia—Prednisone—ankylosing spondylitis	0.000396	0.00207	CcSEcCtD
Ponatinib—Haemoglobin—Dexamethasone—ankylosing spondylitis	0.000392	0.00205	CcSEcCtD
Ponatinib—Haemoglobin—Betamethasone—ankylosing spondylitis	0.000392	0.00205	CcSEcCtD
Ponatinib—Erectile dysfunction—Prednisone—ankylosing spondylitis	0.00039	0.00204	CcSEcCtD
Ponatinib—Haemorrhage—Betamethasone—ankylosing spondylitis	0.00039	0.00204	CcSEcCtD
Ponatinib—Haemorrhage—Dexamethasone—ankylosing spondylitis	0.00039	0.00204	CcSEcCtD
Ponatinib—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.000389	0.00203	CcSEcCtD
Ponatinib—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.000386	0.00202	CcSEcCtD
Ponatinib—Arrhythmia—Triamcinolone—ankylosing spondylitis	0.000384	0.002	CcSEcCtD
Ponatinib—Weight decreased—Prednisone—ankylosing spondylitis	0.000384	0.002	CcSEcCtD
Ponatinib—Vision blurred—Prednisolone—ankylosing spondylitis	0.000383	0.002	CcSEcCtD
Ponatinib—Arrhythmia—Methylprednisolone—ankylosing spondylitis	0.000383	0.002	CcSEcCtD
Ponatinib—Hyperglycaemia—Prednisone—ankylosing spondylitis	0.000382	0.002	CcSEcCtD
Ponatinib—Visual impairment—Betamethasone—ankylosing spondylitis	0.000375	0.00196	CcSEcCtD
Ponatinib—Visual impairment—Dexamethasone—ankylosing spondylitis	0.000375	0.00196	CcSEcCtD
Ponatinib—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.000375	0.00196	CcSEcCtD
Ponatinib—Erythema—Triamcinolone—ankylosing spondylitis	0.000374	0.00195	CcSEcCtD
Ponatinib—Erythema—Methylprednisolone—ankylosing spondylitis	0.000373	0.00195	CcSEcCtD
Ponatinib—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000373	0.00195	CcSEcCtD
Ponatinib—Acute coronary syndrome—Prednisone—ankylosing spondylitis	0.000373	0.00195	CcSEcCtD
Ponatinib—Myocardial infarction—Prednisone—ankylosing spondylitis	0.00037	0.00194	CcSEcCtD
Ponatinib—Neuropathy peripheral—Prednisone—ankylosing spondylitis	0.00037	0.00194	CcSEcCtD
Ponatinib—Breast disorder—Methotrexate—ankylosing spondylitis	0.00037	0.00194	CcSEcCtD
Ponatinib—Eye disorder—Dexamethasone—ankylosing spondylitis	0.000364	0.0019	CcSEcCtD
Ponatinib—Eye disorder—Betamethasone—ankylosing spondylitis	0.000364	0.0019	CcSEcCtD
Ponatinib—Back pain—Triamcinolone—ankylosing spondylitis	0.000362	0.00189	CcSEcCtD
Ponatinib—Angiopathy—Betamethasone—ankylosing spondylitis	0.000353	0.00185	CcSEcCtD
Ponatinib—Angiopathy—Dexamethasone—ankylosing spondylitis	0.000353	0.00185	CcSEcCtD
Ponatinib—Hypertension—Prednisolone—ankylosing spondylitis	0.000351	0.00183	CcSEcCtD
Ponatinib—Arrhythmia—Betamethasone—ankylosing spondylitis	0.000348	0.00182	CcSEcCtD
Ponatinib—Arrhythmia—Dexamethasone—ankylosing spondylitis	0.000348	0.00182	CcSEcCtD
Ponatinib—Pancreatitis—Methotrexate—ankylosing spondylitis	0.000347	0.00182	CcSEcCtD
Ponatinib—Alopecia—Dexamethasone—ankylosing spondylitis	0.000344	0.0018	CcSEcCtD
Ponatinib—Alopecia—Betamethasone—ankylosing spondylitis	0.000344	0.0018	CcSEcCtD
Ponatinib—Haemoglobin—Prednisone—ankylosing spondylitis	0.000341	0.00178	CcSEcCtD
Ponatinib—Abdominal discomfort—Methotrexate—ankylosing spondylitis	0.00034	0.00178	CcSEcCtD
Ponatinib—Haemorrhage—Prednisone—ankylosing spondylitis	0.000339	0.00177	CcSEcCtD
Ponatinib—Erythema—Dexamethasone—ankylosing spondylitis	0.000339	0.00177	CcSEcCtD
Ponatinib—Erythema—Betamethasone—ankylosing spondylitis	0.000339	0.00177	CcSEcCtD
Ponatinib—Pancytopenia—Methotrexate—ankylosing spondylitis	0.000336	0.00176	CcSEcCtD
Ponatinib—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.000333	0.00174	CcSEcCtD
Ponatinib—Oedema—Prednisolone—ankylosing spondylitis	0.000332	0.00173	CcSEcCtD
Ponatinib—Neutropenia—Methotrexate—ankylosing spondylitis	0.000331	0.00173	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Methotrexate—ankylosing spondylitis	0.000329	0.00172	CcSEcCtD
Ponatinib—Erectile dysfunction—Methotrexate—ankylosing spondylitis	0.000326	0.00171	CcSEcCtD
Ponatinib—Cough—Triamcinolone—ankylosing spondylitis	0.000326	0.0017	CcSEcCtD
Ponatinib—Hypertension—Triamcinolone—ankylosing spondylitis	0.000323	0.00169	CcSEcCtD
Ponatinib—Hypertension—Methylprednisolone—ankylosing spondylitis	0.000322	0.00168	CcSEcCtD
Ponatinib—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.000321	0.00168	CcSEcCtD
Ponatinib—Myalgia—Triamcinolone—ankylosing spondylitis	0.000318	0.00166	CcSEcCtD
Ponatinib—Pneumonia—Methotrexate—ankylosing spondylitis	0.000318	0.00166	CcSEcCtD
Ponatinib—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.000318	0.00166	CcSEcCtD
Ponatinib—Myalgia—Methylprednisolone—ankylosing spondylitis	0.000318	0.00166	CcSEcCtD
Ponatinib—Eye disorder—Prednisone—ankylosing spondylitis	0.000317	0.00166	CcSEcCtD
Ponatinib—Infestation—Methotrexate—ankylosing spondylitis	0.000316	0.00165	CcSEcCtD
Ponatinib—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000316	0.00165	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000315	0.00165	CcSEcCtD
Ponatinib—Flushing—Prednisone—ankylosing spondylitis	0.000315	0.00165	CcSEcCtD
Ponatinib—Dry mouth—Triamcinolone—ankylosing spondylitis	0.000311	0.00163	CcSEcCtD
Ponatinib—Stomatitis—Methotrexate—ankylosing spondylitis	0.000308	0.00161	CcSEcCtD
Ponatinib—Angiopathy—Prednisone—ankylosing spondylitis	0.000308	0.00161	CcSEcCtD
Ponatinib—Oedema—Triamcinolone—ankylosing spondylitis	0.000305	0.00159	CcSEcCtD
Ponatinib—Arrhythmia—Prednisone—ankylosing spondylitis	0.000303	0.00158	CcSEcCtD
Ponatinib—Infection—Triamcinolone—ankylosing spondylitis	0.000303	0.00158	CcSEcCtD
Ponatinib—Infection—Methylprednisolone—ankylosing spondylitis	0.000302	0.00158	CcSEcCtD
Ponatinib—Insomnia—Prednisolone—ankylosing spondylitis	0.0003	0.00157	CcSEcCtD
Ponatinib—Alopecia—Prednisone—ankylosing spondylitis	0.0003	0.00157	CcSEcCtD
Ponatinib—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000299	0.00156	CcSEcCtD
Ponatinib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000299	0.00156	CcSEcCtD
Ponatinib—Epistaxis—Methotrexate—ankylosing spondylitis	0.000298	0.00156	CcSEcCtD
Ponatinib—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000298	0.00156	CcSEcCtD
Ponatinib—Mental disorder—Prednisone—ankylosing spondylitis	0.000297	0.00155	CcSEcCtD
Ponatinib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000296	0.00155	CcSEcCtD
Ponatinib—Erythema—Prednisone—ankylosing spondylitis	0.000295	0.00154	CcSEcCtD
Ponatinib—Malnutrition—Prednisone—ankylosing spondylitis	0.000295	0.00154	CcSEcCtD
Ponatinib—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000295	0.00154	CcSEcCtD
Ponatinib—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000294	0.00154	CcSEcCtD
Ponatinib—Hypertension—Dexamethasone—ankylosing spondylitis	0.000293	0.00153	CcSEcCtD
Ponatinib—Hypertension—Betamethasone—ankylosing spondylitis	0.000293	0.00153	CcSEcCtD
Ponatinib—Myalgia—Betamethasone—ankylosing spondylitis	0.000289	0.00151	CcSEcCtD
Ponatinib—Myalgia—Dexamethasone—ankylosing spondylitis	0.000289	0.00151	CcSEcCtD
Ponatinib—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000285	0.00149	CcSEcCtD
Ponatinib—Pain—Prednisolone—ankylosing spondylitis	0.000284	0.00148	CcSEcCtD
Ponatinib—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000284	0.00148	CcSEcCtD
Ponatinib—Vision blurred—Prednisone—ankylosing spondylitis	0.000278	0.00145	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000278	0.00145	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000277	0.00145	CcSEcCtD
Ponatinib—Oedema—Betamethasone—ankylosing spondylitis	0.000277	0.00145	CcSEcCtD
Ponatinib—Oedema—Dexamethasone—ankylosing spondylitis	0.000277	0.00145	CcSEcCtD
Ponatinib—Insomnia—Triamcinolone—ankylosing spondylitis	0.000276	0.00144	CcSEcCtD
Ponatinib—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000275	0.00144	CcSEcCtD
Ponatinib—Infection—Dexamethasone—ankylosing spondylitis	0.000275	0.00144	CcSEcCtD
Ponatinib—Infection—Betamethasone—ankylosing spondylitis	0.000275	0.00144	CcSEcCtD
Ponatinib—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000274	0.00143	CcSEcCtD
Ponatinib—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000273	0.00143	CcSEcCtD
Ponatinib—Visual impairment—Methotrexate—ankylosing spondylitis	0.000273	0.00143	CcSEcCtD
Ponatinib—Anaemia—Prednisone—ankylosing spondylitis	0.000273	0.00143	CcSEcCtD
Ponatinib—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000272	0.00142	CcSEcCtD
Ponatinib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000271	0.00142	CcSEcCtD
Ponatinib—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000271	0.00142	CcSEcCtD
Ponatinib—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000271	0.00142	CcSEcCtD
Ponatinib—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000271	0.00142	CcSEcCtD
Ponatinib—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.000269	0.0014	CcSEcCtD
Ponatinib—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000268	0.0014	CcSEcCtD
Ponatinib—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000268	0.0014	CcSEcCtD
Ponatinib—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000268	0.0014	CcSEcCtD
Ponatinib—Eye disorder—Methotrexate—ankylosing spondylitis	0.000265	0.00139	CcSEcCtD
Ponatinib—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.000263	0.00138	CcSEcCtD
Ponatinib—Fatigue—Triamcinolone—ankylosing spondylitis	0.000263	0.00137	CcSEcCtD
Ponatinib—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000262	0.00137	CcSEcCtD
Ponatinib—Pain—Triamcinolone—ankylosing spondylitis	0.000261	0.00136	CcSEcCtD
Ponatinib—Angiopathy—Methotrexate—ankylosing spondylitis	0.000257	0.00134	CcSEcCtD
Ponatinib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000256	0.00134	CcSEcCtD
Ponatinib—Hypertension—Prednisone—ankylosing spondylitis	0.000255	0.00133	CcSEcCtD
Ponatinib—Chills—Methotrexate—ankylosing spondylitis	0.000254	0.00133	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000252	0.00132	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000252	0.00132	CcSEcCtD
Ponatinib—Myalgia—Prednisone—ankylosing spondylitis	0.000251	0.00131	CcSEcCtD
Ponatinib—Arthralgia—Prednisone—ankylosing spondylitis	0.000251	0.00131	CcSEcCtD
Ponatinib—Alopecia—Methotrexate—ankylosing spondylitis	0.000251	0.00131	CcSEcCtD
Ponatinib—Insomnia—Betamethasone—ankylosing spondylitis	0.00025	0.00131	CcSEcCtD
Ponatinib—Insomnia—Dexamethasone—ankylosing spondylitis	0.00025	0.00131	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.00025	0.00131	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000249	0.0013	CcSEcCtD
Ponatinib—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.000249	0.0013	CcSEcCtD
Ponatinib—Paraesthesia—Betamethasone—ankylosing spondylitis	0.000249	0.0013	CcSEcCtD
Ponatinib—Mental disorder—Methotrexate—ankylosing spondylitis	0.000248	0.0013	CcSEcCtD
Ponatinib—Erythema—Methotrexate—ankylosing spondylitis	0.000247	0.00129	CcSEcCtD
Ponatinib—Malnutrition—Methotrexate—ankylosing spondylitis	0.000247	0.00129	CcSEcCtD
Ponatinib—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.000244	0.00127	CcSEcCtD
Ponatinib—Dyspepsia—Betamethasone—ankylosing spondylitis	0.000244	0.00127	CcSEcCtD
Ponatinib—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000241	0.00126	CcSEcCtD
Ponatinib—Oedema—Prednisone—ankylosing spondylitis	0.000241	0.00126	CcSEcCtD
Ponatinib—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000241	0.00126	CcSEcCtD
Ponatinib—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000241	0.00126	CcSEcCtD
Ponatinib—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000241	0.00126	CcSEcCtD
Ponatinib—Infection—Prednisone—ankylosing spondylitis	0.000239	0.00125	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000239	0.00125	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000239	0.00125	CcSEcCtD
Ponatinib—Back pain—Methotrexate—ankylosing spondylitis	0.000239	0.00125	CcSEcCtD
Ponatinib—Fatigue—Betamethasone—ankylosing spondylitis	0.000239	0.00125	CcSEcCtD
Ponatinib—Fatigue—Dexamethasone—ankylosing spondylitis	0.000239	0.00125	CcSEcCtD
Ponatinib—Pain—Betamethasone—ankylosing spondylitis	0.000237	0.00124	CcSEcCtD
Ponatinib—Pain—Dexamethasone—ankylosing spondylitis	0.000237	0.00124	CcSEcCtD
Ponatinib—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000236	0.00124	CcSEcCtD
Ponatinib—Skin disorder—Prednisone—ankylosing spondylitis	0.000234	0.00122	CcSEcCtD
Ponatinib—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000233	0.00122	CcSEcCtD
Ponatinib—Vision blurred—Methotrexate—ankylosing spondylitis	0.000233	0.00122	CcSEcCtD
Ponatinib—Anaemia—Methotrexate—ankylosing spondylitis	0.000228	0.00119	CcSEcCtD
Ponatinib—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000226	0.00118	CcSEcCtD
Ponatinib—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000226	0.00118	CcSEcCtD
Ponatinib—Leukopenia—Methotrexate—ankylosing spondylitis	0.000221	0.00115	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.00022	0.00115	CcSEcCtD
Ponatinib—Dizziness—Prednisolone—ankylosing spondylitis	0.000219	0.00115	CcSEcCtD
Ponatinib—Asthenia—Triamcinolone—ankylosing spondylitis	0.000219	0.00114	CcSEcCtD
Ponatinib—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000219	0.00114	CcSEcCtD
Ponatinib—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000219	0.00114	CcSEcCtD
Ponatinib—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000219	0.00114	CcSEcCtD
Ponatinib—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000219	0.00114	CcSEcCtD
Ponatinib—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000218	0.00114	CcSEcCtD
Ponatinib—Insomnia—Prednisone—ankylosing spondylitis	0.000218	0.00114	CcSEcCtD
Ponatinib—Paraesthesia—Prednisone—ankylosing spondylitis	0.000216	0.00113	CcSEcCtD
Ponatinib—Pruritus—Triamcinolone—ankylosing spondylitis	0.000216	0.00113	CcSEcCtD
Ponatinib—Cough—Methotrexate—ankylosing spondylitis	0.000215	0.00113	CcSEcCtD
Ponatinib—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000215	0.00113	CcSEcCtD
Ponatinib—Dyspepsia—Prednisone—ankylosing spondylitis	0.000212	0.00111	CcSEcCtD
Ponatinib—Myalgia—Methotrexate—ankylosing spondylitis	0.00021	0.0011	CcSEcCtD
Ponatinib—Arthralgia—Methotrexate—ankylosing spondylitis	0.00021	0.0011	CcSEcCtD
Ponatinib—Decreased appetite—Prednisone—ankylosing spondylitis	0.00021	0.0011	CcSEcCtD
Ponatinib—Rash—Prednisolone—ankylosing spondylitis	0.000209	0.00109	CcSEcCtD
Ponatinib—Dermatitis—Prednisolone—ankylosing spondylitis	0.000209	0.00109	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000209	0.00109	CcSEcCtD
Ponatinib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000208	0.00109	CcSEcCtD
Ponatinib—Fatigue—Prednisone—ankylosing spondylitis	0.000208	0.00109	CcSEcCtD
Ponatinib—Headache—Prednisolone—ankylosing spondylitis	0.000208	0.00109	CcSEcCtD
Ponatinib—Constipation—Prednisone—ankylosing spondylitis	0.000206	0.00108	CcSEcCtD
Ponatinib—Dizziness—Triamcinolone—ankylosing spondylitis	0.000202	0.00105	CcSEcCtD
Ponatinib—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000201	0.00105	CcSEcCtD
Ponatinib—Infection—Methotrexate—ankylosing spondylitis	0.0002	0.00105	CcSEcCtD
Ponatinib—Asthenia—Dexamethasone—ankylosing spondylitis	0.000199	0.00104	CcSEcCtD
Ponatinib—Asthenia—Betamethasone—ankylosing spondylitis	0.000199	0.00104	CcSEcCtD
Ponatinib—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000198	0.00103	CcSEcCtD
Ponatinib—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000197	0.00103	CcSEcCtD
Ponatinib—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000197	0.00103	CcSEcCtD
Ponatinib—Nausea—Prednisolone—ankylosing spondylitis	0.000197	0.00103	CcSEcCtD
Ponatinib—Pruritus—Dexamethasone—ankylosing spondylitis	0.000196	0.00102	CcSEcCtD
Ponatinib—Pruritus—Betamethasone—ankylosing spondylitis	0.000196	0.00102	CcSEcCtD
Ponatinib—Skin disorder—Methotrexate—ankylosing spondylitis	0.000196	0.00102	CcSEcCtD
Ponatinib—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.000195	0.00102	CcSEcCtD
Ponatinib—Vomiting—Triamcinolone—ankylosing spondylitis	0.000194	0.00101	CcSEcCtD
Ponatinib—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000194	0.00101	CcSEcCtD
Ponatinib—Rash—Triamcinolone—ankylosing spondylitis	0.000192	0.00101	CcSEcCtD
Ponatinib—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000192	0.001	CcSEcCtD
Ponatinib—Rash—Methylprednisolone—ankylosing spondylitis	0.000192	0.001	CcSEcCtD
Ponatinib—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000192	0.001	CcSEcCtD
Ponatinib—Headache—Triamcinolone—ankylosing spondylitis	0.000191	0.000999	CcSEcCtD
Ponatinib—Headache—Methylprednisolone—ankylosing spondylitis	0.000191	0.000997	CcSEcCtD
Ponatinib—Abdominal pain—Prednisone—ankylosing spondylitis	0.000191	0.000996	CcSEcCtD
Ponatinib—Body temperature increased—Prednisone—ankylosing spondylitis	0.000191	0.000996	CcSEcCtD
Ponatinib—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000189	0.00099	CcSEcCtD
Ponatinib—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000189	0.00099	CcSEcCtD
Ponatinib—KIT—Immune System—ERAP1—ankylosing spondylitis	0.000187	0.00169	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000187	0.00169	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL1R2—ankylosing spondylitis	0.000187	0.00169	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—IL1RN—ankylosing spondylitis	0.000187	0.00169	CbGpPWpGaD
Ponatinib—FGFR4—Innate Immune System—TLR4—ankylosing spondylitis	0.000185	0.00167	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—HLA-C—ankylosing spondylitis	0.000185	0.00167	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000184	0.00166	CbGpPWpGaD
Ponatinib—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000184	0.000959	CcSEcCtD
Ponatinib—Dizziness—Betamethasone—ankylosing spondylitis	0.000183	0.000957	CcSEcCtD
Ponatinib—Dizziness—Dexamethasone—ankylosing spondylitis	0.000183	0.000957	CcSEcCtD
Ponatinib—Insomnia—Methotrexate—ankylosing spondylitis	0.000182	0.000952	CcSEcCtD
Ponatinib—Nausea—Triamcinolone—ankylosing spondylitis	0.000181	0.000947	CcSEcCtD
Ponatinib—Paraesthesia—Methotrexate—ankylosing spondylitis	0.000181	0.000946	CcSEcCtD
Ponatinib—Nausea—Methylprednisolone—ankylosing spondylitis	0.000181	0.000945	CcSEcCtD
Ponatinib—FGFR2—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000181	0.00163	CbGpPWpGaD
Ponatinib—Dyspnoea—Methotrexate—ankylosing spondylitis	0.00018	0.000939	CcSEcCtD
Ponatinib—SRC—Innate Immune System—CARD9—ankylosing spondylitis	0.000178	0.00161	CbGpPWpGaD
Ponatinib—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000178	0.00161	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—ERAP1—ankylosing spondylitis	0.000178	0.00161	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000178	0.0016	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—ERAP1—ankylosing spondylitis	0.000177	0.0016	CbGpPWpGaD
Ponatinib—Dyspepsia—Methotrexate—ankylosing spondylitis	0.000177	0.000927	CcSEcCtD
Ponatinib—Vomiting—Betamethasone—ankylosing spondylitis	0.000176	0.00092	CcSEcCtD
Ponatinib—Vomiting—Dexamethasone—ankylosing spondylitis	0.000176	0.00092	CcSEcCtD
Ponatinib—FGFR1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000175	0.00158	CbGpPWpGaD
Ponatinib—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000175	0.000915	CcSEcCtD
Ponatinib—PDGFRA—Innate Immune System—HLA-C—ankylosing spondylitis	0.000175	0.00158	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CARD9—ankylosing spondylitis	0.000175	0.00158	CbGpPWpGaD
Ponatinib—Rash—Betamethasone—ankylosing spondylitis	0.000175	0.000912	CcSEcCtD
Ponatinib—Rash—Dexamethasone—ankylosing spondylitis	0.000175	0.000912	CcSEcCtD
Ponatinib—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000174	0.000911	CcSEcCtD
Ponatinib—Dermatitis—Betamethasone—ankylosing spondylitis	0.000174	0.000911	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000174	0.000909	CcSEcCtD
Ponatinib—Fatigue—Methotrexate—ankylosing spondylitis	0.000174	0.000908	CcSEcCtD
Ponatinib—Headache—Betamethasone—ankylosing spondylitis	0.000173	0.000906	CcSEcCtD
Ponatinib—Headache—Dexamethasone—ankylosing spondylitis	0.000173	0.000906	CcSEcCtD
Ponatinib—Asthenia—Prednisone—ankylosing spondylitis	0.000173	0.000904	CcSEcCtD
Ponatinib—Pain—Methotrexate—ankylosing spondylitis	0.000172	0.0009	CcSEcCtD
Ponatinib—LYN—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000172	0.00155	CbGpPWpGaD
Ponatinib—KIT—Immune System—CARD9—ankylosing spondylitis	0.000171	0.00155	CbGpPWpGaD
Ponatinib—Pruritus—Prednisone—ankylosing spondylitis	0.000171	0.000891	CcSEcCtD
Ponatinib—FGFR1—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000168	0.00152	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000168	0.00152	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL1R2—ankylosing spondylitis	0.000165	0.00149	CbGpPWpGaD
Ponatinib—Diarrhoea—Prednisone—ankylosing spondylitis	0.000165	0.000862	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000165	0.000861	CcSEcCtD
Ponatinib—Nausea—Dexamethasone—ankylosing spondylitis	0.000164	0.000859	CcSEcCtD
Ponatinib—Nausea—Betamethasone—ankylosing spondylitis	0.000164	0.000859	CcSEcCtD
Ponatinib—FGFR4—Immune System—CD79A—ankylosing spondylitis	0.000164	0.00148	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL1R2—ankylosing spondylitis	0.000164	0.00148	CbGpPWpGaD
Ponatinib—FGFR3—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000163	0.00148	CbGpPWpGaD
Ponatinib—LYN—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000163	0.00147	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CARD9—ankylosing spondylitis	0.000163	0.00147	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CARD9—ankylosing spondylitis	0.000162	0.00147	CbGpPWpGaD
Ponatinib—FGFR3—Innate Immune System—HLA-B—ankylosing spondylitis	0.000162	0.00146	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—HLA-C—ankylosing spondylitis	0.000159	0.00144	CbGpPWpGaD
Ponatinib—Dizziness—Prednisone—ankylosing spondylitis	0.000159	0.000833	CcSEcCtD
Ponatinib—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000159	0.000832	CcSEcCtD
Ponatinib—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000159	0.000832	CcSEcCtD
Ponatinib—LYN—Immune System—ERAP1—ankylosing spondylitis	0.000157	0.00141	CbGpPWpGaD
Ponatinib—LCK—Disease—ANTXR2—ankylosing spondylitis	0.000156	0.00141	CbGpPWpGaD
Ponatinib—ABL1—Immune System—ERAP1—ankylosing spondylitis	0.000156	0.00141	CbGpPWpGaD
Ponatinib—FGFR3—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000155	0.0014	CbGpPWpGaD
Ponatinib—BCR—Disease—HLA-A—ankylosing spondylitis	0.000155	0.0014	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—HLA-C—ankylosing spondylitis	0.000154	0.00139	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000154	0.00139	CbGpPWpGaD
Ponatinib—Vomiting—Prednisone—ankylosing spondylitis	0.000153	0.000801	CcSEcCtD
Ponatinib—LCK—HIV Infection—HLA-A—ankylosing spondylitis	0.000152	0.00137	CbGpPWpGaD
Ponatinib—Rash—Prednisone—ankylosing spondylitis	0.000152	0.000794	CcSEcCtD
Ponatinib—Dermatitis—Prednisone—ankylosing spondylitis	0.000152	0.000794	CcSEcCtD
Ponatinib—Headache—Prednisone—ankylosing spondylitis	0.000151	0.000789	CcSEcCtD
Ponatinib—LYN—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000151	0.00136	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000148	0.00134	CbGpPWpGaD
Ponatinib—Asthenia—Methotrexate—ankylosing spondylitis	0.000145	0.000755	CcSEcCtD
Ponatinib—FGFR3—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000144	0.0013	CbGpPWpGaD
Ponatinib—Nausea—Prednisone—ankylosing spondylitis	0.000143	0.000748	CcSEcCtD
Ponatinib—LYN—Immune System—CARD9—ankylosing spondylitis	0.000143	0.00129	CbGpPWpGaD
Ponatinib—FGFR3—Innate Immune System—CRP—ankylosing spondylitis	0.000143	0.00129	CbGpPWpGaD
Ponatinib—Pruritus—Methotrexate—ankylosing spondylitis	0.000143	0.000745	CcSEcCtD
Ponatinib—ABL1—Immune System—CARD9—ankylosing spondylitis	0.000143	0.00129	CbGpPWpGaD
Ponatinib—LCK—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000141	0.00127	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL1RN—ankylosing spondylitis	0.000138	0.00125	CbGpPWpGaD
Ponatinib—SRC—Disease—ANTXR2—ankylosing spondylitis	0.000138	0.00125	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000138	0.00124	CbGpPWpGaD
Ponatinib—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000138	0.00072	CcSEcCtD
Ponatinib—FGFR3—Innate Immune System—TLR4—ankylosing spondylitis	0.000137	0.00124	CbGpPWpGaD
Ponatinib—FGFR2—Disease—B3GNT2—ankylosing spondylitis	0.000137	0.00124	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000135	0.00122	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL1R2—ankylosing spondylitis	0.000135	0.00122	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—IL1A—ankylosing spondylitis	0.000135	0.00122	CbGpPWpGaD
Ponatinib—KIT—Disease—B3GNT2—ankylosing spondylitis	0.000135	0.00122	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—CD40LG—ankylosing spondylitis	0.000134	0.00121	CbGpPWpGaD
Ponatinib—LCK—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000133	0.0012	CbGpPWpGaD
Ponatinib—Dizziness—Methotrexate—ankylosing spondylitis	0.000133	0.000696	CcSEcCtD
Ponatinib—BCR—Signaling Pathways—MMP3—ankylosing spondylitis	0.000131	0.00118	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000129	0.00117	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000128	0.00116	CbGpPWpGaD
Ponatinib—LCK—Immune System—ERAP1—ankylosing spondylitis	0.000128	0.00116	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000128	0.00116	CbGpPWpGaD
Ponatinib—Vomiting—Methotrexate—ankylosing spondylitis	0.000128	0.00067	CcSEcCtD
Ponatinib—FGFR1—Disease—B3GNT2—ankylosing spondylitis	0.000128	0.00115	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—HLA-B—ankylosing spondylitis	0.000127	0.00115	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—B3GNT2—ankylosing spondylitis	0.000127	0.00115	CbGpPWpGaD
Ponatinib—Rash—Methotrexate—ankylosing spondylitis	0.000127	0.000664	CcSEcCtD
Ponatinib—Dermatitis—Methotrexate—ankylosing spondylitis	0.000127	0.000663	CcSEcCtD
Ponatinib—LCK—Innate Immune System—HLA-C—ankylosing spondylitis	0.000127	0.00114	CbGpPWpGaD
Ponatinib—Headache—Methotrexate—ankylosing spondylitis	0.000126	0.00066	CcSEcCtD
Ponatinib—LCK—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000124	0.00112	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—CD79A—ankylosing spondylitis	0.000122	0.0011	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000122	0.0011	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL1R2—ankylosing spondylitis	0.00012	0.00108	CbGpPWpGaD
Ponatinib—Nausea—Methotrexate—ankylosing spondylitis	0.00012	0.000625	CcSEcCtD
Ponatinib—FGFR4—Immune System—HLA-A—ankylosing spondylitis	0.000118	0.00107	CbGpPWpGaD
Ponatinib—LCK—Immune System—CARD9—ankylosing spondylitis	0.000117	0.00106	CbGpPWpGaD
Ponatinib—SRC—Immune System—ERAP1—ankylosing spondylitis	0.000114	0.00103	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—B3GNT2—ankylosing spondylitis	0.000113	0.00102	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000113	0.00102	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—CRP—ankylosing spondylitis	0.000113	0.00102	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000112	0.00101	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—HLA-C—ankylosing spondylitis	0.000112	0.00101	CbGpPWpGaD
Ponatinib—FGFR1—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000111	0.00101	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—HLA-B—ankylosing spondylitis	0.000111	0.00101	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.00011	0.000997	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—HLA-C—ankylosing spondylitis	0.00011	0.00099	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—HLA-B—ankylosing spondylitis	0.000109	0.000987	CbGpPWpGaD
Ponatinib—FGFR4—Disease—HLA-A—ankylosing spondylitis	0.000109	0.000985	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—TLR4—ankylosing spondylitis	0.000108	0.000975	CbGpPWpGaD
Ponatinib—KIT—Immune System—HLA-C—ankylosing spondylitis	0.000108	0.000972	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000108	0.000971	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000107	0.000965	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000105	0.000948	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000105	0.000946	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000104	0.000943	CbGpPWpGaD
Ponatinib—SRC—Immune System—CARD9—ankylosing spondylitis	0.000104	0.000938	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000104	0.000937	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—HLA-B—ankylosing spondylitis	0.000103	0.000935	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HLA-C—ankylosing spondylitis	0.000102	0.000923	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HLA-C—ankylosing spondylitis	0.000102	0.00092	CbGpPWpGaD
Ponatinib—FGFR1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000101	0.000908	CbGpPWpGaD
Ponatinib—PDGFRA—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.0001	0.000906	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL1A—ankylosing spondylitis	9.97e-05	0.0009	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—HLA-B—ankylosing spondylitis	9.96e-05	0.0009	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—HLA-B—ankylosing spondylitis	9.94e-05	0.000897	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—CD40LG—ankylosing spondylitis	9.91e-05	0.000895	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—HLA-A—ankylosing spondylitis	9.9e-05	0.000894	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—CRP—ankylosing spondylitis	9.84e-05	0.000889	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—HLA-A—ankylosing spondylitis	9.73e-05	0.000878	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—CRP—ankylosing spondylitis	9.66e-05	0.000873	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—PTGER4—ankylosing spondylitis	9.57e-05	0.000864	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL1RN—ankylosing spondylitis	9.52e-05	0.00086	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—TLR4—ankylosing spondylitis	9.43e-05	0.000852	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—HLA-B—ankylosing spondylitis	9.43e-05	0.000851	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL1RN—ankylosing spondylitis	9.35e-05	0.000845	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—CD79A—ankylosing spondylitis	9.27e-05	0.000837	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—TLR4—ankylosing spondylitis	9.27e-05	0.000837	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—HLA-A—ankylosing spondylitis	9.23e-05	0.000834	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—CD40LG—ankylosing spondylitis	9.22e-05	0.000832	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—MMP3—ankylosing spondylitis	9.21e-05	0.000832	CbGpPWpGaD
Ponatinib—LCK—Disease—B3GNT2—ankylosing spondylitis	9.21e-05	0.000832	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—HLA-A—ankylosing spondylitis	9.21e-05	0.000832	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—CRP—ankylosing spondylitis	9.17e-05	0.000828	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—CRP—ankylosing spondylitis	9.15e-05	0.000826	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—HLA-B—ankylosing spondylitis	9.13e-05	0.000824	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—HLA-B—ankylosing spondylitis	9.09e-05	0.00082	CbGpPWpGaD
Ponatinib—LYN—Immune System—HLA-C—ankylosing spondylitis	8.99e-05	0.000812	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HLA-C—ankylosing spondylitis	8.95e-05	0.000808	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL1RN—ankylosing spondylitis	8.88e-05	0.000802	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL1RN—ankylosing spondylitis	8.85e-05	0.0008	CbGpPWpGaD
Ponatinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	8.8e-05	0.000795	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—TLR4—ankylosing spondylitis	8.79e-05	0.000794	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—TLR4—ankylosing spondylitis	8.77e-05	0.000792	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—HLA-B—ankylosing spondylitis	8.77e-05	0.000792	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—HLA-A—ankylosing spondylitis	8.73e-05	0.000789	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CD79A—ankylosing spondylitis	8.36e-05	0.000755	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PTGER4—ankylosing spondylitis	8.34e-05	0.000753	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—CRP—ankylosing spondylitis	8.33e-05	0.000752	CbGpPWpGaD
Ponatinib—KIT—Immune System—CD79A—ankylosing spondylitis	8.21e-05	0.000742	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—CD79A—ankylosing spondylitis	8.2e-05	0.000741	CbGpPWpGaD
Ponatinib—SRC—Disease—B3GNT2—ankylosing spondylitis	8.16e-05	0.000737	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—HLA-A—ankylosing spondylitis	8.12e-05	0.000733	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—CRP—ankylosing spondylitis	8.07e-05	0.000729	CbGpPWpGaD
Ponatinib—FGFR3—Disease—HLA-A—ankylosing spondylitis	8.06e-05	0.000728	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—CRP—ankylosing spondylitis	8.03e-05	0.000725	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—TLR4—ankylosing spondylitis	7.99e-05	0.000721	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL1RN—ankylosing spondylitis	7.81e-05	0.000705	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CD79A—ankylosing spondylitis	7.79e-05	0.000704	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CD79A—ankylosing spondylitis	7.77e-05	0.000702	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL1RN—ankylosing spondylitis	7.77e-05	0.000702	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—TLR4—ankylosing spondylitis	7.74e-05	0.000699	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—TLR4—ankylosing spondylitis	7.7e-05	0.000695	CbGpPWpGaD
Ponatinib—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	7.69e-05	0.000695	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—CD40LG—ankylosing spondylitis	7.55e-05	0.000682	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—HLA-B—ankylosing spondylitis	7.48e-05	0.000676	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—B3GNT2—ankylosing spondylitis	7.47e-05	0.000675	CbGpPWpGaD
Ponatinib—LCK—Immune System—HLA-C—ankylosing spondylitis	7.37e-05	0.000665	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—HLA-B—ankylosing spondylitis	7.18e-05	0.000649	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD79A—ankylosing spondylitis	6.86e-05	0.000619	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL1A—ankylosing spondylitis	6.86e-05	0.000619	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD79A—ankylosing spondylitis	6.83e-05	0.000616	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CD40LG—ankylosing spondylitis	6.82e-05	0.000616	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MMP3—ankylosing spondylitis	6.82e-05	0.000615	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL1A—ankylosing spondylitis	6.73e-05	0.000608	CbGpPWpGaD
Ponatinib—KIT—Immune System—CD40LG—ankylosing spondylitis	6.69e-05	0.000605	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—CD40LG—ankylosing spondylitis	6.69e-05	0.000604	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—HLA-A—ankylosing spondylitis	6.66e-05	0.000601	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—HLA-B—ankylosing spondylitis	6.62e-05	0.000598	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—CRP—ankylosing spondylitis	6.61e-05	0.000597	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PTGER4—ankylosing spondylitis	6.58e-05	0.000595	CbGpPWpGaD
Ponatinib—SRC—Immune System—HLA-C—ankylosing spondylitis	6.52e-05	0.000589	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—HLA-B—ankylosing spondylitis	6.48e-05	0.000586	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PTGER4—ankylosing spondylitis	6.47e-05	0.000584	CbGpPWpGaD
Ponatinib—SRC—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	6.42e-05	0.00058	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL1RN—ankylosing spondylitis	6.4e-05	0.000578	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL1A—ankylosing spondylitis	6.39e-05	0.000577	CbGpPWpGaD
Ponatinib—KDR—Developmental Biology—TNF—ankylosing spondylitis	6.39e-05	0.000577	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL1A—ankylosing spondylitis	6.37e-05	0.000576	CbGpPWpGaD
Ponatinib—KIT—Immune System—HLA-B—ankylosing spondylitis	6.37e-05	0.000575	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—HLA-B—ankylosing spondylitis	6.36e-05	0.000574	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CD40LG—ankylosing spondylitis	6.35e-05	0.000574	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—TLR4—ankylosing spondylitis	6.34e-05	0.000573	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CD40LG—ankylosing spondylitis	6.34e-05	0.000572	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PTGER4—ankylosing spondylitis	6.14e-05	0.000554	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PTGER4—ankylosing spondylitis	6.12e-05	0.000553	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HLA-B—ankylosing spondylitis	6.04e-05	0.000546	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HLA-B—ankylosing spondylitis	6.03e-05	0.000544	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—HLA-A—ankylosing spondylitis	6.01e-05	0.000543	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MMP3—ankylosing spondylitis	5.94e-05	0.000536	CbGpPWpGaD
Ponatinib—KIT—Immune System—HLA-A—ankylosing spondylitis	5.9e-05	0.000533	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—HLA-A—ankylosing spondylitis	5.89e-05	0.000532	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—CRP—ankylosing spondylitis	5.86e-05	0.000529	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CRP—ankylosing spondylitis	5.73e-05	0.000518	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL1RN—ankylosing spondylitis	5.67e-05	0.000512	CbGpPWpGaD
Ponatinib—KIT—Immune System—CRP—ankylosing spondylitis	5.63e-05	0.000508	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL1A—ankylosing spondylitis	5.62e-05	0.000508	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD79A—ankylosing spondylitis	5.62e-05	0.000508	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—TLR4—ankylosing spondylitis	5.61e-05	0.000507	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HLA-A—ankylosing spondylitis	5.6e-05	0.000506	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL1A—ankylosing spondylitis	5.6e-05	0.000505	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD40LG—ankylosing spondylitis	5.59e-05	0.000505	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HLA-A—ankylosing spondylitis	5.59e-05	0.000504	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD40LG—ankylosing spondylitis	5.56e-05	0.000502	CbGpPWpGaD
Ponatinib—FGFR2—Disease—HLA-A—ankylosing spondylitis	5.55e-05	0.000501	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—TLR4—ankylosing spondylitis	5.49e-05	0.000496	CbGpPWpGaD
Ponatinib—KIT—Disease—HLA-A—ankylosing spondylitis	5.45e-05	0.000492	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PTGER4—ankylosing spondylitis	5.4e-05	0.000488	CbGpPWpGaD
Ponatinib—KIT—Immune System—TLR4—ankylosing spondylitis	5.4e-05	0.000487	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—B3GNT2—ankylosing spondylitis	5.36e-05	0.000484	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CRP—ankylosing spondylitis	5.34e-05	0.000482	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CRP—ankylosing spondylitis	5.33e-05	0.000481	CbGpPWpGaD
Ponatinib—LYN—Immune System—HLA-B—ankylosing spondylitis	5.32e-05	0.00048	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HLA-B—ankylosing spondylitis	5.29e-05	0.000478	CbGpPWpGaD
Ponatinib—FGFR1—Disease—HLA-A—ankylosing spondylitis	5.17e-05	0.000467	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—HLA-A—ankylosing spondylitis	5.16e-05	0.000466	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—TLR4—ankylosing spondylitis	5.12e-05	0.000462	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—TLR4—ankylosing spondylitis	5.11e-05	0.000461	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD79A—ankylosing spondylitis	4.98e-05	0.000449	CbGpPWpGaD
Ponatinib—LYN—Immune System—HLA-A—ankylosing spondylitis	4.93e-05	0.000445	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HLA-A—ankylosing spondylitis	4.9e-05	0.000443	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—TNF—ankylosing spondylitis	4.7e-05	0.000425	CbGpPWpGaD
Ponatinib—LYN—Immune System—CRP—ankylosing spondylitis	4.7e-05	0.000424	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MMP3—ankylosing spondylitis	4.69e-05	0.000423	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CRP—ankylosing spondylitis	4.68e-05	0.000422	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—B3GNT2—ankylosing spondylitis	4.64e-05	0.000419	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL1A—ankylosing spondylitis	4.61e-05	0.000416	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MMP3—ankylosing spondylitis	4.6e-05	0.000416	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD40LG—ankylosing spondylitis	4.58e-05	0.000414	CbGpPWpGaD
Ponatinib—LYN—Immune System—TLR4—ankylosing spondylitis	4.51e-05	0.000407	CbGpPWpGaD
Ponatinib—ABL1—Immune System—TLR4—ankylosing spondylitis	4.48e-05	0.000405	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTGER4—ankylosing spondylitis	4.43e-05	0.0004	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MMP3—ankylosing spondylitis	4.37e-05	0.000395	CbGpPWpGaD
Ponatinib—LCK—Immune System—HLA-B—ankylosing spondylitis	4.36e-05	0.000394	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MMP3—ankylosing spondylitis	4.36e-05	0.000394	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—TNF—ankylosing spondylitis	4.14e-05	0.000373	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—TNF—ankylosing spondylitis	4.12e-05	0.000372	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL1A—ankylosing spondylitis	4.08e-05	0.000368	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD40LG—ankylosing spondylitis	4.06e-05	0.000366	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	4.04e-05	0.000365	CbGpPWpGaD
Ponatinib—LCK—Immune System—HLA-A—ankylosing spondylitis	4.04e-05	0.000365	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTGER4—ankylosing spondylitis	3.92e-05	0.000354	CbGpPWpGaD
Ponatinib—SRC—Immune System—HLA-B—ankylosing spondylitis	3.86e-05	0.000348	CbGpPWpGaD
Ponatinib—LCK—Immune System—CRP—ankylosing spondylitis	3.85e-05	0.000348	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP3—ankylosing spondylitis	3.84e-05	0.000347	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	3.81e-05	0.000344	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	3.8e-05	0.000343	CbGpPWpGaD
Ponatinib—LCK—Disease—HLA-A—ankylosing spondylitis	3.73e-05	0.000337	CbGpPWpGaD
Ponatinib—LCK—Immune System—TLR4—ankylosing spondylitis	3.69e-05	0.000333	CbGpPWpGaD
Ponatinib—SRC—Immune System—HLA-A—ankylosing spondylitis	3.57e-05	0.000323	CbGpPWpGaD
Ponatinib—SRC—Immune System—CRP—ankylosing spondylitis	3.41e-05	0.000308	CbGpPWpGaD
Ponatinib—SRC—Disease—HLA-A—ankylosing spondylitis	3.3e-05	0.000298	CbGpPWpGaD
Ponatinib—SRC—Immune System—TLR4—ankylosing spondylitis	3.27e-05	0.000295	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP3—ankylosing spondylitis	3.15e-05	0.000285	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—TNF—ankylosing spondylitis	3e-05	0.000271	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP3—ankylosing spondylitis	2.79e-05	0.000252	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	2.49e-05	0.000225	CbGpPWpGaD
